Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease-Reference-Cited by-同舟云学术

Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease

Published:2015-04-06 Issue:3 Volume:1 Page:205-211
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:Eur Heart J Cardiovasc Pharmacother

Author:

Campo Gianluca,Pavasini Rita,Biscaglia Simone,Contoli Marco,Ceconi Claudio

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/article-pdf/1/3/205/1100636/pvv019.pdf

Reference60 articles.

1. 2014 ESC/EACTS Guidelines on myocardial revascularization

2. Global Initiative for chronic obstructive lung disease – global strategy for the diagnosis, management and prevention for chronic obstructive pulmonary disease. Updated 2014.

3. Cardiovascular Disease in COPD

4. Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD

5. Impact of COPD on Long-term Outcome After ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-cardiac comorbidities in heart failure: an update on diagnostic and management strategies;Minerva Medica;2024-06

2. Prognostic impact of chronic obstructive pulmonary disease in patients with heart failure with mildly reduced ejection fraction;Respiratory Medicine;2024-03

3. Effect of chronic lung diseases on angina pectoris among Indian adults: longitudinal ageing study in India;Scientific Reports;2024-01-29

4. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD);Journal of Toxicology and Environmental Health, Part B;2023-05-14

5. Lipid plaque burden in NSTE-ACS patients with or without COPD: insights from the SCAP Trial;Minerva Cardiology and Angiology;2021-12